After eight weeks of stay-at-home and quarentine orders, biotech leaders are starting to confront the long-term consequences of COVD-19 on their businesses. For a small share of the industry, there has been a need to shift attention and resources to technologies with the potential to directly influence the prevention, dianosis, or treatment of the virus.